Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

Por Jurczak, W, Zinzani, P L, Gaidano, G, Goy, A, Provencio, M, Nagy, Z, Robak, T, Maddocks, K, Buske, C, Ambarkhane, S, Winderlich, M, Dirnberger-Hertweck, M, Korolkiewicz, R, Blum, K A
Publicado no Ann Oncol (2018)

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

Por Rule, S, Jurczak, W, Jerkeman, M, Rusconi, C, Trneny, M, Offner, F, Caballero, D, Joao, C, Witzens-Harig, M, Hess, G, Bence-Bruckler, I, Cho, S-G, Thieblemont, C, Zhou, W, Henninger, T, Goldberg, J, Vermeulen, J, Dreyling, M
Publicado no Leukemia (2018)

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

Por Connors, J.M., Jurczak, W., Straus, D.J., Ansell, S.M., Kim, W.S., Gallamini, A., Younes, A., Alekseev, S., Illés, Á., Picardi, M., Lech-Maranda, E., Oki, Y., Feldman, T., Smolewski, P., Savage, K.J., Bartlett, N.L., Walewski, J., Chen, R., Ramchandren, R., Zinzani, P.L., Cunningham, D., Rosta, A., Josephson, N.C., Song, E., Sachs, J., Liu, R., Jolin, H.A., Huebner, D., Radford, J.
Publicado no N Engl J Med (2017)